Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort

Inflammatory Bowel Diseases

Volumn 22, Issue 7, 2016, Pages 1662-1669

  Khorrami, Sam ^a   Ginard, Daniel ^a   Marín Jiménez, Ignacio ^b   Chaparro, María ^c   Sierra, Mónica ^d   Aguas, Mariam ^e   Sicilia, Beatriz ^f   García Sánchez, Valle ^g   Suarez, Cristina ^h   Villoria, Albert ⁱ   Taxonera, Carlos ^j   Velasco Guardado, Antonio ^k   Martínez González, Javier ^l   Gisbert, Javier P ^c  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Crohn's disease; IL 12; IL 23; inflammatory bowel disease; refractory; ustekinumab

Indexed keywords

USTEKINUMAB; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTESTINE RESECTION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OPEN STUDY; ORCHITIS; OTITIS; OUTCOME ASSESSMENT; PHARYNGITIS; PREDICTION; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SKIN DEFECT; TREATMENT DURATION; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; RECTUM FISTULA; RETREATMENT; SKIN FISTULA; SPAIN; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; CUTANEOUS FISTULA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECTAL FISTULA; RETREATMENT; RETROSPECTIVE STUDIES; SPAIN; USTEKINUMAB;

EID: 84976291747     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000842     Document Type: Article

References (29)

1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549
3. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767
4. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with metaanalysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613-623
5. Gisbert JP, Chaparro M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? Scand J Gastroenterol. 2015;50:379-386
6. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-5610
7. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007; 13:26-28
8. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-1463
9. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359-2370
10. Kikly K, Liu L, Na S, et al. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18:670-675
11. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674
12. Papp KA, Langley RG, Lobwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684
13. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-789
14. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796-804
15. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135: 1130-1141
16. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn' disease. N Engl J Med. 2012; 367:1519-1528
17. Toedter GP, Blank M, Lang Y, et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn' disease. Am J Gastroenterol. 2009;104:2768-2773
18. Sandborn W, Gasink C, Blank M, et al. A multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn's disease refractory to anti-TFNa: UNITI-1. Inflamm Bowel Dis. 2016;22(Suppl 1):S1
19. Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn' disease\-The McGill experience. J Crohns Colitis. 2014;8:1516-1522
20. Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14: 242-250
21. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58: 1152-1167
22. Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-A therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517-524
23. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-g-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577
24. Guerra I, Gisbert JP. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents. Expert Rev Gastroenterol Hepatol. 2013;7:41-48
25. Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol. 2014;39:751-752
26. Nunes T, Etchevers MJ, Merino O, et al. Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis. 2013;19:23-29
27. De Cruz P, Kamm MA, Prideaux L, et al. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis. 2012;18:758-777
28. Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther. 2012;35:625-633
29. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706-714